Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

IINSMED Inc

EconomyAI buildoutMarket MapFundsWatchlist
Log in
I

INSMED Inc

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
    Sep 21, 2026News Releases | Insmed Incorporated
  • Insmed Expands Community Impact During Fifth Annual Global Day of Good
    Sep 16, 2026News Releases | Insmed Incorporated
  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    Sep 4, 2026News Releases | Insmed Incorporated
  • Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
    Sep 3, 2026News Releases | Insmed Incorporated
  • Insmed to Present at September 2026 Investor Conferences
    Aug 26, 2026News Releases | Insmed Incorporated
  • BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
    Aug 24, 2026News Releases | Insmed Incorporated
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions